Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 2/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2588875 | 1.00 | CYP2D6 (0.54) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL10106632 | 1.00 | CYP2D6 (0.54) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| Hydrochloric Acid SCHEMBL6647751 | 0.98 | CYP2D6 (0.52) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| Hydrochloric Acid SCHEMBL6674386 | 0.98 | CYP2D6 (0.52) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL10952283 | 0.83 | CYP2D6 (0.43) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL1808926 | 0.83 | ANPEP (0.40) | CYP2D6CYP2C19DPP4ANPEPDNPEP | |
| SCHEMBL7223053 | 0.83 | ANPEP (0.40) | CYP2D6CYP2C19DPP4ANPEPDNPEP | |
| Bromide SCHEMBL10953299 | 0.82 | CYP2D6 (0.42) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL6295279 | 0.82 | CYP2D6 (0.42) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL7330431 | 0.81 | CYP2D6 (0.50) | CYP2D6CYP2C19MMP1MMP8HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019493-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015004075-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-15 | — | — | WO | disclosed |
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-20100003276-A1 | Methods for treating anthrax and inhibiting lethal factor | HERMES JEFFERY D | 2010-01-07 | — | — | US | disclosed |
| US-7504425-B2 | Compounds useful in the treatment of anthrax and inhibiting lethal factor | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003276-A1 | Methods for treating anthrax and inhibiting lethal factor | ANTXR2, SERPINB1, APAF1 | CYP2D6 4661/4885CYP2C19 4580/4885MMP1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.